Metropolitan Life Insurance Co NY Purchases 1,040 Shares of Regenxbio Inc (NASDAQ:RGNX)

Metropolitan Life Insurance Co NY raised its position in shares of Regenxbio Inc (NASDAQ:RGNX) by 10.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,299 shares of the biotechnology company’s stock after acquiring an additional 1,040 shares during the quarter. Metropolitan Life Insurance Co NY’s holdings in Regenxbio were worth $402,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of RGNX. NEXT Financial Group Inc boosted its position in Regenxbio by 89.8% during the 3rd quarter. NEXT Financial Group Inc now owns 2,566 shares of the biotechnology company’s stock valued at $91,000 after acquiring an additional 1,214 shares in the last quarter. Royal Bank of Canada boosted its position in Regenxbio by 36.2% during the 2nd quarter. Royal Bank of Canada now owns 3,910 shares of the biotechnology company’s stock valued at $201,000 after acquiring an additional 1,040 shares in the last quarter. Virginia Retirement Systems ET AL bought a new stake in Regenxbio during the 2nd quarter valued at approximately $216,000. Ellington Management Group LLC bought a new stake in Regenxbio during the 2nd quarter valued at approximately $216,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors boosted its position in Regenxbio by 28.3% during the 3rd quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 7,250 shares of the biotechnology company’s stock valued at $258,000 after acquiring an additional 1,600 shares in the last quarter. 78.44% of the stock is currently owned by institutional investors and hedge funds.

In related news, CEO Kenneth T. Mills sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $39.75, for a total value of $397,500.00. Following the completion of the transaction, the chief executive officer now directly owns 251,000 shares in the company, valued at approximately $9,977,250. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 13.80% of the stock is owned by insiders.

RGNX has been the topic of several research reports. Leerink Swann raised Regenxbio from an “underperform” rating to a “market perform” rating in a research report on Tuesday, August 20th. They noted that the move was a valuation call. Zacks Investment Research cut Regenxbio from a “buy” rating to a “hold” rating in a research report on Saturday, October 26th. BidaskClub cut Regenxbio from a “buy” rating to a “hold” rating in a research report on Thursday. Evercore ISI reissued a “buy” rating and issued a $65.00 price target on shares of Regenxbio in a research report on Monday, November 11th. Finally, Chardan Capital set a $150.00 price target on Regenxbio and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $76.71.

Shares of RGNX opened at $42.01 on Friday. The company has a quick ratio of 11.49, a current ratio of 11.49 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average price is $39.61 and its 200-day moving average price is $41.50. Regenxbio Inc has a 52 week low of $30.38 and a 52 week high of $63.21. The stock has a market cap of $1.57 billion, a P/E ratio of 17.65 and a beta of 0.86.

Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.03). Regenxbio had a negative return on equity of 18.74% and a negative net margin of 99.57%. The company had revenue of $14.70 million during the quarter, compared to the consensus estimate of $7.46 million. During the same period in the prior year, the firm earned ($0.56) earnings per share. The business’s revenue for the quarter was up 177.0% compared to the same quarter last year. On average, equities analysts anticipate that Regenxbio Inc will post -2.8 EPS for the current year.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Recommended Story: How big is the FinTech market?

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.